AMAG Pharmaceuticals to Host Analyst Day on May 22, 2019 in New York
May 17 2019 - 8:00AM
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that it
will host an Analyst Day for the investment community on Wednesday,
May 22, 2019 from 8:30 a.m. to 12:00 p.m. Eastern Time. Members of
AMAG’s management team and key opinion leaders will provide updates
on the company’s development assets and commercial programs.
In-person attendance requires advanced registration. Please contact
Linda Lennox at llennox@amagpharma.com for further information. A
live webcast of the event will be accessible through the Investors
section of the company’s website at www.amagpharma.com. A replay of
the webcast will also be available and archived on the site.
Featured Key Opinion Leader Speakers
include:
VyleesiTM (hypoactive sexual desire
disorder (HSDD)); PDUFA date June 23, 2019 |
|
- Sheryl Kingsberg, PhD, Division Chief of Behavioral Medicine,
University Hospitals Cleveland Medical Center, Cleveland,
OH
- David Portman, MD, Director Emeritus, Columbus Center for
Women's Health Research, Adjunct Instructor, Ohio State University,
Columbus, OH
- HSDD patient - fireside chat with HSDD patient and Dr. Sheryl
Kingsberg
|
Ciraparantag (in development as an
anticoagulant reversal agent) |
|
- Jack Ansell, MD, Professor of Medicine, Hofstra Northwell
School of Medicine, NY
- Joseph Bledsoe, MD, Department of Emergency Medicine,
Intermountain Healthcare, Salt Lake City, UT, Stanford University
medical faculty through Intermountain-Stanford collaborative
- C. Michael Gibson, MD, Interventional cardiologist,
cardiovascular researcher, Beth Israel Deaconess Medical Center,
Boston, MA
|
AMAG-423 (in development for the treatment
of severe preeclampsia) |
|
- John Barton, MD, Baptist Health Medical Center, Lexington,
KY
- Baha Sibai, MD, Texas Medical Center, Houston, TX
|
About AMAGAMAG is a
pharmaceutical company focused on bringing innovative products to
patients with unmet medical needs. The company does this by
leveraging our development and commercial expertise to invest in
and grow its pharmaceutical products across a range of therapeutic
areas, including women’s health. For additional company
information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® and "Feraheme® and the logo and designs
are registered trademarks of AMAG Pharmaceuticals, Inc. VyleesiTM
is a trademark of AMAG Pharmaceuticals, Inc. Other trademarks
referenced in this release are the property of their respective
owners.
AMAG Pharmaceuticals
Contact:Linda LennoxVice President, Investor
RelationsO: 617-498-2846M: 908-627-3424
AMAG Pharmaceuticals (NASDAQ:AMAG)
Historical Stock Chart
From Aug 2024 to Sep 2024
AMAG Pharmaceuticals (NASDAQ:AMAG)
Historical Stock Chart
From Sep 2023 to Sep 2024